-+ 0.00%
-+ 0.00%
-+ 0.00%

Collegium raises 2026 net product revenue outlook to $865-$895 million

PUBT·05/12/2026 11:32:53
Listen to the news
Collegium raises 2026 net product revenue outlook to $865-$895 million
  • Collegium Pharmaceutical raised full-year 2026 guidance following completion of AZSTARYS acquisition from Corium Therapeutics.
  • Product revenues, net forecast lifted to USD 865-895 million from USD 805-825 million.
  • Adjusted EBITDA outlook increased to USD 475-500 million from USD 455-475 million.
  • AZSTARYS expected to contribute USD 60-70 million of net revenue during remainder of 2026; JORNAY PM revenue, net guidance kept at USD 190-200 million.
  • Acquisition valued at about USD 650 million in cash, funded by about USD 350 million of cash on hand, USD 300 million from delayed draw term loan; potential additional consideration up to USD 135 million tied to milestones.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collegium Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120731PRIMZONEFULLFEED9718284) on May 12, 2026, and is solely responsible for the information contained therein.